WO1998017214A1 - Method for treating dementia due to aids - Google Patents
Method for treating dementia due to aids Download PDFInfo
- Publication number
- WO1998017214A1 WO1998017214A1 PCT/US1997/019184 US9719184W WO9817214A1 WO 1998017214 A1 WO1998017214 A1 WO 1998017214A1 US 9719184 W US9719184 W US 9719184W WO 9817214 A1 WO9817214 A1 WO 9817214A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- dementia due
- effective amount
- hiv disease
- treating
- Prior art date
Links
- 0 C*Oc1n[s]nc1C1=CCCN(C)C1 Chemical compound C*Oc1n[s]nc1C1=CCCN(C)C1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Definitions
- This invention provides a method for treating or alleviating the symptoms of dementia due to AIDS, comprising administering an effective amount of 3- (4-hexyloxy-l, 2, 5- thiadiazol-3-yl) -1,2,5, 6-tetrahydro-l-methylpyridine .
- HIV disease Human immunodeficiency virus (HIV) disease may often result in the patient being further incapacitated due to the serious psychological disorder, Dementia Due to HIV Disease (characterized in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (American Psychiatric Association, 1994) DSM-IV as catagory 294.9). Such Dementia can result in hospitalization of the patient, stress for caretakers, and increased medical expense.
- HIV Human immunodeficiency virus
- the present invention relates to a method of treating Dementia Due to HIV Disease. More specifically, the invention provides a method of treating Dementia Due to HIV Disease in humans using 3- (4-hexyloxy-l, 2, 5-thiadiazol-3-yl) -1, 2, 5, 6- tetrahydro-1-methylpyridine .
- the compounds employed in the method of the present invention are known. Methods of preparing the compounds, as well as pharmaceutical formulations containing the compounds, are taught by Sauerberg in U.S. Pat. No. 5,043,345 herein incorporated by reference .
- the present invention provides a method for treating Dementia Due to HIV Disease in humans comprising administering to a human in need thereof, an effective amount of a compound of Formula I:
- the term "effective amount”, as used herein, represents an amount of compound necessary to prevent or treat a human susceptible to or suffering from Dementia due to HIV Disease following administration to such human.
- the active compound is effective over a wide dosage range. For example, dosages per day will normally fall within the range of about 0.005 to about 500 mg/kg of body weight. In the treatment of adult humans, the range of about 0.05 to about 100 mg/kg, in single or divided doses, is preferred.
- the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.
- the present compound may be administered orally to humans susceptible to or suffering from Dementia Due to HIV Disease, the compound is particularly well suited to be administered transdermally. When the compound is delivered transdermally, it is preferred that the effective amount is from about 50mg to about lOOmg per day delivery of base compound. It is especially preferred that such patch delivers an effective amount for about three to seven days.
- the compound may further be delivered by a variety of other pharmaceutically accepted routes including, but in no way limited to parenterally, subcutaneous, intranasal, intramuscular and intravenous routes.
- Such formulations may be designed to provide delayed or controlled release using formulation techniques which are known in the art.
- treating includes prophylaxis of a physical and/or mental condition or amelioration or elimination of the developed physical and/or mental condition once it has been established or alleviation of the characteristic symptoms of such condition.
- the term "Dementia Due to HIV Disease” refers to a disorder that upon neuropathological examination may commonly involve diffuse multifocal destruction of the white matter and subcortical structures.
- the spinal fluid may show normal or slightly elevated protein and a mild lymphocytosis, and HIV can usually be isolated directly from the cerebrospinal fluid.
- Dementia associated with HIV is typically characterized by slowness, poor concentration, difficulties with problem solving, and forgetfulness .
- Behavioral manifestations most commonly include apathy and social withdrawal, and occasionally these may be accompanied by delirium, delusions, or hallucinations .
- Tremor, impaired rapid repetitive movements, imbalance, ataxia, hypertonia, generalized hyperreflexia, positive frontal release signs, and impaired pursuit and saccadic eye movements may be presented on physical examination.
- DSM-IV-R Diagnostic and Statistical Manual of Mental Disorders, Revised, 4th Ed. (1994) .
- the DSM-IV-R was prepared by the Task Force on Nomenclature and Statistics of the American Psychiatric Association, and provides clear descriptions of diagnostic catagories. The skilled artisan will recognize that there are alternative nomenclatures, nosologies, and classification systems for pathologic psychological conditions and that these systems evolve with medical scientific progress.
- the compounds employed in the invention are not believed to act via the GABA/benzodiazepine, 5HT1A, or Dl receptor systems in humans. Rather, the activity of the present compound as a treatment for Dementia Due to HIV Disease is believed to be based upon modulation of muscarinic cholinergic receptors. However, the mechanism by which the present compounds function is not necessarily the mechanism stated supra . , and the present invention is not limited by any mode of operation. The following Examples are studies to establish the usefulness of the named compounds for treating Dementia Due to HIV Disease.
- Treatment groups are compared with respect to the number and percent of patients who ever had the symptom during the double-blind portion of the study (visits 5 through 33) , at a severity that was worse than during the baseline visits (1 through 4) .
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10519635A JP2001502696A (en) | 1996-10-23 | 1997-10-23 | How to treat AIDS dementia |
CA002269506A CA2269506A1 (en) | 1996-10-23 | 1997-10-23 | Method for treating dementia due to aids |
EP97912879A EP0934040A1 (en) | 1996-10-23 | 1997-10-23 | Method for treating dementia due to aids |
AU49957/97A AU4995797A (en) | 1996-10-23 | 1997-10-23 | Method for treating dementia due to aids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2973696P | 1996-10-23 | 1996-10-23 | |
US60/029,736 | 1996-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998017214A1 true WO1998017214A1 (en) | 1998-04-30 |
Family
ID=21850604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/019184 WO1998017214A1 (en) | 1996-10-23 | 1997-10-23 | Method for treating dementia due to aids |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0934040A1 (en) |
JP (1) | JP2001502696A (en) |
AU (1) | AU4995797A (en) |
CA (1) | CA2269506A1 (en) |
WO (1) | WO1998017214A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000032185A1 (en) * | 1998-11-27 | 2000-06-08 | Sanochemia Pharmazeutika Aktiengesellschaft | Use of effectors of the central cholinergic nervous system |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4826843A (en) * | 1985-07-08 | 1989-05-02 | Bristol-Myers | Cerebral function enhancing diazinylpiperidine derivatives |
US5043345A (en) * | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
US5232929A (en) * | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
-
1997
- 1997-10-23 AU AU49957/97A patent/AU4995797A/en not_active Abandoned
- 1997-10-23 JP JP10519635A patent/JP2001502696A/en active Pending
- 1997-10-23 CA CA002269506A patent/CA2269506A1/en not_active Abandoned
- 1997-10-23 WO PCT/US1997/019184 patent/WO1998017214A1/en not_active Application Discontinuation
- 1997-10-23 EP EP97912879A patent/EP0934040A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4826843A (en) * | 1985-07-08 | 1989-05-02 | Bristol-Myers | Cerebral function enhancing diazinylpiperidine derivatives |
US5043345A (en) * | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
US5232929A (en) * | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000032185A1 (en) * | 1998-11-27 | 2000-06-08 | Sanochemia Pharmazeutika Aktiengesellschaft | Use of effectors of the central cholinergic nervous system |
Also Published As
Publication number | Publication date |
---|---|
EP0934040A1 (en) | 1999-08-11 |
CA2269506A1 (en) | 1998-04-30 |
JP2001502696A (en) | 2001-02-27 |
AU4995797A (en) | 1998-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11419850B2 (en) | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases | |
US5965571A (en) | Cholinesterase inhibitors for treatment of Parkinson's disease | |
US8097633B2 (en) | Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium | |
EP0230370A2 (en) | Use of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration | |
MX2012001814A (en) | Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions. | |
CA2132509A1 (en) | Treatment of anxiety with the aid of (s)-(-)-.alpha.- ethyl-2-oxo-1-pyrrolidineacetamide | |
PT1051170E (en) | USE OF AMINOMETILCHROMANS SUBSTITUTED FOR THE PREVENTION OF NEURONAL DEGENERATION AND FOR THE PROMOTION OF NEURONAL REGENERATION | |
US6284771B1 (en) | Method for treating schizophrenia | |
WO1998005291A2 (en) | Method for treating mental retardation | |
US5011841A (en) | Treatment of depression | |
US6117890A (en) | Method for treating bipolar disorder | |
WO1998017214A1 (en) | Method for treating dementia due to aids | |
EP2490685B1 (en) | Causal therapy of diseases or conditions associated with cns or pns demyelination | |
AU716972B2 (en) | Method for treating bipolar disorder | |
KR100692235B1 (en) | New use of angiotensin ii antagonists | |
PT1492539E (en) | Statin therapy for enhancing cognitive maintenance | |
US6642262B2 (en) | Riluzole and alpha-tocopherol combination | |
JP2001523724A (en) | Citicoline for treating motor neuron disease and demyelination disease | |
WO2018220457A1 (en) | Vitamin b1 in high doses for use in the medical treatment of motor symptoms of some sporadic neurodegenerative diseases, of genetic origin, and of cluster headache and of migraine headache | |
RU2805061C2 (en) | Treatment of demyelinating diseases | |
US6090829A (en) | Method for treating excessive aggression | |
US20220362202A1 (en) | Drug For Treating And Preventing Dementia | |
EP0116238A1 (en) | Therapeutic compositions and their use in enhancing brain function | |
US4742076A (en) | Etodolac for lowering rheumatoid factor | |
WO1998046225A1 (en) | Method for treating schizophrenia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09284778 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997912879 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2269506 Country of ref document: CA Ref country code: CA Ref document number: 2269506 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 1998 519635 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1997912879 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997912879 Country of ref document: EP |